The Valley Desk

NCT00094653 · Interventional trial

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Overall registry status Completed

Phase 3

Conditions Melanoma, Metastases

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov